leadf
logo-loader
viewAnteris Technologies Ltd

Admedus Ltd proud to unveil its valves publicly for the first time in London

Admedus Ltd's (ASX:AHZ) CEO Wayne Paterson caught up with Proactive's Andrew Scott while in London.

The firm recently made what's been described as a transformational move to sell off its CardioCel® and VascuCel® patch business.

Paterson says the focus is now firmly on the Adapt division - advancing its Transcatheter Aortic Valve Replacement (TAVR) program and other potential products.

Quick facts: Anteris Technologies Ltd

Price: 4.02 AUD

ASX:AVR
Market: ASX
Market Cap: $23.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Anteris Technologies 'delivering on its goals despite pandemic'

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are...

on 6/7/20

2 min read